Tukysa (tucatinib) — CareFirst (Caremark)
HER2-positive biliary tract cancers (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma)
Initial criteria
- Member has locally advanced, unresectable, resected gross residual (R2) or metastatic HER2-positive biliary tract cancer
- Medication will be used in combination with trastuzumab
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months